Chardan Capital Reiterates Buy Rating on CRISPR

Summary

Chardan Capital has reiterated a “buy” rating for CRISPR Therapeutics (CRSP) with a price target of $82.00, suggesting a potential upside of 47.51%. Other analysts have provided positive ratings, with price targets ranging from $65.00 to $105.00. Despite a recent stock decline, CRISPR’s quarterly earnings exceeded expectations, reporting a loss of $1.29 EPS. Insider trading activity includes significant stock purchases by director Simeon George. The stock currently has a consensus rating of “hold” and a market cap of $4.80 billion.Market Beat

Impact Analysis

This event is at the company level, focusing specifically on CRISPR Therapeutics. The reiteration of a buy rating by Chardan Capital suggests confidence in the company’s future performance despite recent stock declines. The price target of $82.00 indicates a potential upside, which may encourage investor interest.Market Beat Historical ratings show varied opinions, with Piper Sandler setting a target of $105.00 and Goldman Sachs previously downgrading to a target of $47.00, reflecting mixed sentiment and potential market volatility.Market Beat+ 2 The buy rating and insider stock purchases may act as positive signals, potentially leading to increased investor confidence and stock price appreciation. Investors should consider these factors alongside CRISPR’s earnings performance and market position when making investment decisions.